[{"orgOrder":0,"company":"Veranova","sponsor":"Nutriband","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Veranova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Veranova \/ Nutriband","highestDevelopmentStatusID":"6","companyTruncated":"Veranova \/ Nutriband"}]

Find Clinical Drug Pipeline Developments & Deals by Veranova

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Fentanyl

                          Therapeutic Area : Neurology

                          Study Phase : Phase I

                          Sponsor : Nutriband

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          Details : Nutriband signs licensing agreement for Bitrex (denatonium benzoate) as an aversive agent for its Aversa Fentanyl (Fentanyl) abuse deterrent fentanyl transdermal patch.

                          Product Name : Aversa

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          September 20, 2024

                          Lead Product(s) : Fentanyl

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Nutriband

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          Veranova